Detalles de la búsqueda
1.
Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study.
Int J Neuropsychopharmacol;
24(12): 965-976, 2021 12 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34324636
2.
Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations.
J Clin Psychopharmacol;
39(6): 567-574, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31688450
3.
Genome-wide association study of paliperidone efficacy.
Pharmacogenet Genomics;
27(1): 7-18, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27846195
4.
Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
Int J Neuropsychopharmacol;
19(7)2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26902950
5.
Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy.
Br J Clin Pharmacol;
82(5): 1364-1370, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27333588
6.
Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia.
Pharmacogenet Genomics;
25(4): 173-85, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25714000
7.
Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable: A Database Report and Case Study.
J Clin Psychopharmacol;
39(2): 180-182, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30811377
8.
Schizophrenia comorbid with panic disorder: evidence for distinct cognitive profiles.
Psychiatry Res;
197(3): 206-11, 2012 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-22417926
9.
Carbon dioxide induction of panic anxiety in schizophrenia with auditory hallucinations.
Psychiatry Res;
189(1): 38-42, 2011 Aug 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-21719111
10.
Characteristics of patients with major depressive disorder switching SSRI/SNRI therapy compared with those augmenting with an atypical antipsychotic in a real-world setting.
Curr Med Res Opin;
37(8): 1377-1384, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33818238
11.
Abnormal semantic processing of threat words associated with excitement and hostility symptoms in schizophrenia.
Schizophr Res;
228: 394-402, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33549981
12.
The effects of a staff-training program in behavior management and social-learning principles on staff-patient interactions within a psychiatric rehabilitation inpatient unit.
Am J Orthopsychiatry;
90(4): 419-431, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32134309
13.
Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study.
Schizophr Res Cogn;
20: 100173, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32154123
14.
Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies.
Neuropsychiatr Dis Treat;
16: 1533-1542, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32606705
15.
Attention shaping: a reward-based learning method to enhance skills training outcomes in schizophrenia.
Schizophr Bull;
35(1): 222-32, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18212327
16.
Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation.
Neuropsychiatr Dis Treat;
15: 731-737, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30962688
17.
Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies.
Braz J Psychiatry;
41(6): 499-510, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30994855
18.
Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population.
Neuropsychiatr Dis Treat;
15: 587-602, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30863080
19.
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia.
Neuropsychiatr Dis Treat;
15: 1365-1379, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31190840
20.
Relationship between antipsychotic blood levels and treatment failure during the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
Schizophr Res;
201: 324-328, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29804929